CytomX Therapeutics, the Probody™ therapeutics company, today announced the presentation of new data demonstrating preclinical proof of concept of the Company’s Jagged Probody blocking Jagged-dependent Notch signaling for the treatment of cancer. These data were presented for the first time during a poster session today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held Oct. 19-23, 2013, in Boston.
Help employers find you! Check out all the jobs and post your resume.
